Hemostatic pad EVARREST™

wound surgery

EVARREST is an innovative solution that can stop challenging bleeding on the first attempt1 and is backed by a variety of controlled, clinical trials, and demonstrated superior hemostatic efficacy.1-4 Hemostasis is achieved with EVARREST Fibrin Sealant Patch when the formed fibrin clot integrates with the patch component and adheres to the wound surface, thus also providing a physical barrier to bleeding. About this Device EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component. Clinical Evidence EVARREST demonstrated superior hemostatic efficacy in 4 randomized controlled clinical trials across a spectrum of challenging bleeding situations and surgical procedures.1-4 Trial 1: Soft Tissue hemorrhage (ITT population=90). Trial 2: Normal and Abnormal liver resection hemorrhage (ITT population=84). Trial 3: Anatomic and nonanatomic liver resection hemorrhage (ITT population=102). Trial 4: Aortic reconstruction (ITT population=156). Features & Benefits Proven Superior to TachoSil Patch EVARREST was clinically proven to achieve hemostasis more reliably than TachoSil Patch in a multicenter, randomized study in aortic reconstruction surgery,chieving hemostasis in 3 minutes in 78.8% of cases vs 46.7% (per protocol; ITT population=141). Blood Seeps in, Doesn’t Pool Underneath After appropriate application and manual compression for 3 minutes, blood seeps into the EVARREST patch rather than pooling beneath it. Blood activates fibrinogen